Neurocrine biosciences announces u.s. fda accepts new drug application for ingrezza® (valbenazine) oral granules sprinkle formulation

Prescription drug user fee act (pdufa) target action date set for april 30, 2024 san diego , sept. 14, 2023 /prnewswire/ -- neurocrine biosciences, inc.  (nasdaq: nbix) today announced the u.s. food and drug administration (fda) has accepted its new drug application (nda) for ingrezza® (valbenazine) oral granules, a new sprinkle formulation of ingrezza® (valbenazine) capsules for oral administration.
NBIX Ratings Summary
NBIX Quant Ranking